Were Crystal Adam’s Tango Therapeutics share sales made under a Rule 10b5-1 plan?

Yes. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025. Such plans pre-schedule trades, helping separate routine liquidity or diversification moves from discretionary, market-timing decisions by corporate insiders.

What does the Tango Therapeutics Form 4 reveal about net share changes for Crystal Adam?

The Form 4 shows Crystal Adam exercised options for 27,000 shares and sold 27,000 shares, resulting in a net sell of 27,000 shares when aggregating open-market activity. Despite this, she continues to hold a substantial stake of 142,743 shares directly in Tango Therapeutics.

Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tango Therapeutics, Inc. President, R&D Crystal Adam reported an exercise-and-sell transaction in company common stock. She exercised stock options for 27,000 shares at $5.20 per share, then sold a total of 27,000 shares in open-market trades at weighted-average prices around $29–$30.

The filing shows two sale blocks: 7,371 shares at a weighted-average price of $30.2464 and 19,629 shares at $29.3424. After these transactions, Adam directly holds 142,743 shares of common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 27,000 shares ($798,908)

Net Sell 4 txns

Insider Crystal Adam

Role President, R&D

Sold 27,000 shs ($799K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	27,000	$0.00	--
Exercise	Common Stock	27,000	$5.20	$140K
Sale	Common Stock	19,629	$29.3424	$576K
Sale	Common Stock	7,371	$30.2464	$223K

Holdings After Transaction: Stock Option (Right to Buy) — 314,040 shares (Direct, null); Common Stock — 142,743 shares (Direct, null)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $29.72 to $30.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Shares sold: 27,000 shares First sale block price: $30.2464 per share Second sale block price: $29.3424 per share +3 more

6 metrics

Shares sold 27,000 shares Total common shares sold in open-market transactions on July 1, 2026

First sale block price $30.2464 per share Weighted-average price for 7,371 shares sold

Second sale block price $29.3424 per share Weighted-average price for 19,629 shares sold

Option exercise price $5.20 per share Exercise price for 27,000 stock options converted into common stock

Post-transaction holdings 142,743 shares Common shares directly held by Crystal Adam after transactions

Rule 10b5-1 plan adoption date October 27, 2025 Date the trading plan governing these sales was adopted

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), weighted average sales price, derivative exercise/conversion, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) transaction covering 27,000.0000 shares at a conversion price of 5.2000."

weighted average sales price financial

"Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share."

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion for 27,000.0000 common shares at $5.2000."

open-market sale financial

"transaction_action: open-market sale of common stock with transaction code S."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 07:24 PM Accepted by SEC EDGAR 07/02/2026 - 07:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last)

(First)

(Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		M⁽¹⁾		27,000	A	$5.2	142,743	D
Common Stock	07/01/2026		S⁽¹⁾		19,629	D	$29.3424⁽²⁾	123,114	D
Common Stock	07/01/2026		S⁽¹⁾		7,371	D	$30.2464⁽³⁾	115,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.2	07/01/2026		M⁽¹⁾			27,000	⁽⁴⁾	03/01/2033	Common Stock	27,000	$0	314,040	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $29.72 to $30.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Tango Therapeutics (TNGX) report for Crystal Adam?

Tango Therapeutics reported that President, R&D Crystal Adam exercised options for 27,000 common shares, then sold 27,000 shares in open-market trades. The filing details two sale blocks and confirms these moves were executed under a pre-arranged Rule 10b5-1 trading plan.

How many Tango Therapeutics (TNGX) shares did Crystal Adam sell and at what prices?

Crystal Adam sold a total of 27,000 Tango Therapeutics common shares. She sold 7,371 shares at a weighted-average price of $30.2464 and 19,629 shares at $29.3424, with individual trades ranging between approximately $28.715 and $30.65 per share, according to the filing footnotes.

What stock options did Crystal Adam exercise in the latest Tango Therapeutics Form 4?

In this Form 4, Crystal Adam exercised stock options covering 27,000 Tango Therapeutics common shares at an exercise price of $5.20 per share. The underlying option vests over four years, with 25% vesting on February 27, 2024 and the remainder vesting in 36 monthly installments thereafter.

How many Tango Therapeutics shares does Crystal Adam hold after these transactions?

After completing the option exercise and related sales, Crystal Adam directly holds 142,743 shares of Tango Therapeutics common stock. This post-transaction balance is reported in the Form 4 and reflects her remaining equity position following the net sale of 27,000 shares.